Angiogenesis and the ischaemic heart

European Heart Journal

Volumn 22, Issue 11, 2001, Pages 903-918

  Tabibiazar, R ^a   Rockson, Stanley G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gene therapy; Ischaemia; Therapeutic angiogenesis

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; FIBROBLAST GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR RECEPTOR; INTERLEUKIN 8; PLACENTAL PEPTIDE HORMONE; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; CARDIOVASCULAR DISEASE; GENE THERAPY; HEART MUSCLE ISCHEMIA; HEMODYNAMIC MONITORING; HUMAN; HYPOXIA; LASER; MORBIDITY; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; REVIEW; SHEAR STRESS;

CORONARY VESSELS; HUMANS; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 0034929510     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2000.2372     Document Type: Review

References (187)

1. Tumor angiogenesis: Therapeutic implications
2. Tumor angiogenesis
3. Mechanisms of angiogenesis
4. Embryonic angiogenesis factors
5. Food for starving hearts
6. Angiogenesis in ischemic heart disease
7. Coronary angiogenesis. From morphometry to molecular biology and back
8. Exercise-induced coronary angiogenesis: A review
9. Angiogenesis in skeletal and cardiac muscle
10. Factors involved in capillary growth in the heart
11. Regulating angiogenesis: A new therapeutic strategy
12. Molecular mechanisms of coronary collateral vessel growth
13. Shear stress selectively upregulates intercellular adhesion molecule-1 expression in cultured human vascular endothelial cells
14. Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes
15. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration
16. The effect of fluid shear stress on the migration and proliferation of cultured endothelial cells
17. Flow-dependent regulation of gene expression in vascular endothelial cells
18. Stretch-induced VEGF expression in the heart
19. Bradycardia-induced coronary angiogenesis is dependent on vascular endothelial growth factor
20. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis
21. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells
22. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
23. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells
24. Expression of vascular permeability factor/vascular endothelial growth factor in pig cerebral microvascular endothelial cells and its upregulation by adenosine
25. Regulation of cardiovascular development and physiology by hypoxia-inducible factor 1
26. Angiogenic potency of nucleotide metabolites: Potential role in ischemia-induced vascular growth
27. Hypoxia regulates vascular endothelial growth factor receptor KDR/Flk gene expression through adenosine A2 receptors in retinal capillary endothelial cells
28. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis
29. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide
30. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression
31. Vascular endothelial growth factor expression coincides with coronary vasculogenesis and angiogenesis
32. Interindividual heterogeneity in the hypoxic regulation of VEGF: Significance for the development of the coronary artery collateral circulation
33. Cellular events associated with inflammatory angiogenesis in the mouse cornea
34. Macrophage-derived angiogenesis factors
35. Cellular adhesion molecules. Newly identified mediators of angiogenesis
36. Tumor angiogenesis
37. Control of coronary angiogenesis
38. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro
39. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels
40. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth
41. A novel heart derived inhibitor of vascular cell proliferation. Purification and biological activity
42. Seminars in Medicine of the Beth Israel Hospital. Boston. Clinical applications of research on angiogenesis
43. What is the role of endothelial cells in angiogenesis?
44. Tumour angiogenesis factor for revascularisation in ischaemia and myocardial infarction
45. Angiogenesis factor from human myocardial infarcts
46. Angiogenic factors
47. Regulators of angiogenesis
48. Angiogenic factors: Regulators of blood supply-side biology. FGF, endothelial cell growth factors and angiogenesis: A keystone symposium, Keystone, CO, USA, April 1-7, 1991
49. Acidic fibroblast growth factor and heart development. Role in myocyte proliferation and capillary angiogenesis
50. Molecular biology of the coronary vascular and myocardial responses to ischemia
51. The role of insulin-like and basic fibroblast growth factors on ischemic and infarcted myocardium: A mini review
52. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor
53. Molecular mechanisms of angiogenesis: Fibroblast growth factor signal transduction
54. Heparin-binding angiogenesis factors: Detection by immunological methods
55. The fibroblast growth factor family: Structural and biological properties
56. A heparin-binding angiogenic protein - Basic fibroblast growth factor - Is stored within basement membrane
57. Interactions of FGFs with target cells
58. Fibroblast growth factor receptors (FGFRs) and their roles in limb development
59. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only
60. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo
61. Regrowth of arterial endothelium. Denudation with minimal trauma leads to complete endothelial cell regrowth
62. Effects of acidic fibroblast growth factor on normal and ischemic myocardium
63. Use of vascular endothelial growth factor for therapeutic angiogenesis
64. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis
65. Human vascular permeability factor. Isolation from U937 cells
66. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells
67. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells
68. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries
69. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing
70. Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively
71. Vascular endothelial growth factor B. a novel growth factor for endothelial cells
72. Vascular endothelial growth factors VEGF-B and VEGF-C
73. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice
74. VEGF and VEGF-C: Specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane
75. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia
76. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
77. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
78. The regulation of blood vessel growth by vascular endothelial growth factor
79. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: Implications for coronary angiogenesis
80. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1
81. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
82. Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells
83. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells
84. Vascular endothelial growth factor: Molecular and biological aspects
85. 1-Butyryl-glycerol: A novel angiogenesis factor secreted by differentiating adipocytes
86. Biosynthesis of the vaso-active lipid monobutyrin. Central role of diacylglycerol
87. Neovasculogenic ability of prostaglandins, growth factors, and synthetic chemoattractants
88. PGE2 and angiogenesis
89. Effect of NO, vasodilator prostaglandins, and adenosine on skeletal muscle angiogenic growth factor gene expression
90. Prostaglandins and gangliosides of tumor microenvironment: Their role in angiogenesis
91. Chemical identification of a tumor-derived angiogenic factor
92. Adenosine nucleotides, adenosine and adenine as angiogenesis factors
93. Stimulation of angiogenesis by adenosine on the chick chorioallantoic membrane
94. Adenosine stimulates proliferation of human endothelial cells in culture
95. Angiogenesis induced by degradation products of hyaluronic acid
96. Low molecular weight angiogenesis factors
97. Indirect angiogenic agents do not release fibroblast growth factors from extracellular matrix
98. Experimental angiogenesis in the chorio-allantoic membrane
99. Regulation of adenosine formation by the heart
100. Chronic oral dipyridamole as a 'novel' antianginal drug: The collateral hypothesis
101. Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth
102. Role of nitric oxide in tumor progression: Lessons from experimental tumors
103. Role of nitric oxide in the angiogenesis of avascular tissue
104. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P
105. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia
106. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor
107. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart
108. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart
109. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model
110. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium
111. Reduction in myocardial infarct size by basic fibroblast growth factor following coronary occlusion in a canine model
112. Therapeutic angiogenesis: A comparative study of the angiogenic potential of acidic fibroblast growth factor and heparin
113. The stimulation of neo-angiogenesis in the ischemic heart by the human growth factor FGF
114. Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease
115. Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia
116. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs
117. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury
118. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts
119. Vascular endothelial growth factor administration in chronic myocardial ischemia
120. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart
121. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor
122. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia
123. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion
124. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia
125. Endothelium-dependent relaxation of collateral microvessels after intramuscular gene transfer of vascular endothelial growth factor in a rat model of hindlimb ischemia
126. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion
127. The characterization of the receptor for endothelial cell growth factor by covalent ligand attachment
128. Site-directed neovessel formation in vivo
129. Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors
130. Angiopoietin-1 induces sprouting angiogenesis in vitro
131. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization
132. Increased vascularization in mice overexpressing angiopoietin-1
133. Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2
134. Dell induces integrin signaling and angiogenesis by ligation of alpha Vbeta3
135. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF
136. Human coronary microvessels in diabetes and ischaemia. Morphometric study of autopsy material
137. Acquired coronary angiogenesis after myocardial infarction
138. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188
139. Therapeutic angiogenesis for heart failure
140. Angiogenesis and atherosclerosis. The mandate broadens
141. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice
142. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries
143. Cancer and atherosclerosis: The broad mandate of angiogenesis
144. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb
145. Preclinical and clinical studies with recombinant human basic fibroblast growth factor
146. Therapeutic angiogenesis: Protein and gene therapy delivery strategies
147. Gene therapy - A novel form of drug delivery
148. Adenoviruses as gene-delivery vehicles
149. Gene therapy for therapeutic myocardial angiogenesis: A promising synthesis of two emerging technologies
150. Vascular endothelial growth factor is a secreted angiogenic mitogen
151. Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency
152. Vascular endothelial growth factor: Gene therapy and therapeutic angiogenesis
153. Gene therapy for myocardial angiogenesis
154. Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia
155. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
156. Increased gene expression after liposome-mediated arterial gene transfer associated with intimal smooth muscle cell proliferation. In vitro and in vivo findings in a rabbit model of vascular injury
157. Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo
158. Liposome-mediated gene transfer into human vascular smooth muscle cells
159. Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease
160. Safety and efficacy of in vivo gene transfer into the porcine heart with replication-deficient, recombinant adenovirus vectors
161. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGFI21 cDNA to individuals with clinically significant severe coronary artery disease
162. Intracoronary administration of recombinant fibroblast growth factor-2 (rFGF-2) in patients with severe coronary artery disease: Results of phase 1
163. Double blind, placebo controlled trial of recombinant human vascular endothelial growth factor - The VIVA trial
164. Results of a randomized, double-blind, placebo-controlled study of local perivascular basic fibroblast growth factor (bFGF) treatment in patients undergoing coronary artery bypass surgery
165. Angiographic methods to assess human coronary angiogenesis
166. Use of synchrotron radiation microangiography to assess development of small collateral arteries in a rat model of hindlimb ischemia
167. Therapeutic angiogenesis in ischemic limbs
168. Fibroblast growth factor as therapy for critical limb ischemia: A case report
169. Therapeutic angiogenesis with basic fibroblast growth factor: Technique and early results
170. Direct intramyocardial injection of VEGF results in effective gene transfer for patients with chronic myocardial ischemia
171. Percutaneous transmyocardial laser revascularization: An overview
172. Transventricular revascularization by laser
173. Laser myocardial revascularization
174. Myocardial revascularization by laser: A clinical report
175. Transmyocardial laser revascularization: Results of a multicenter trial with transmyocardial laser revascularization used as sole therapy for end-stage coronary artery disease
176. Initial results of laser-based percutaneous myocardial revascularization for angina pectoris
177. Angiogenesis and growth factor expression in a model of transmyocardial revascularization
178. Transmyocardial laser revascularization and angiogenesis: The potential for therapeutic benefit
179. Angiogenesis in transmyocardial laser revascularization. A nonspecific response to injury
180. Complete reversal of ischemic wall motion abnormalities by combined use of gene therapy with transmyocardial laser revascularization
181. Clinical studies of TMR with the CO2 laser
182. Current status of transmyocardial laser revascularization: Review of the literature
183. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease
184. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina
185. Transmyocardial laser revascularization
186. Percutaneous arterial gene transfer in a rabbit model. Efficiency in normal and balloon-dilated atherosclerotic arteries
187. Subxyphoid access of the normal pericardium: A novel drug delivery technique